CN110167582A - 一种预防和治疗药物性肾损伤的方法 - Google Patents

一种预防和治疗药物性肾损伤的方法 Download PDF

Info

Publication number
CN110167582A
CN110167582A CN201780078117.3A CN201780078117A CN110167582A CN 110167582 A CN110167582 A CN 110167582A CN 201780078117 A CN201780078117 A CN 201780078117A CN 110167582 A CN110167582 A CN 110167582A
Authority
CN
China
Prior art keywords
plasminogen
renal
drug
disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078117.3A
Other languages
English (en)
Chinese (zh)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN110167582A publication Critical patent/CN110167582A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780078117.3A 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法 Pending CN110167582A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016110169 2016-12-15
CNPCT/CN2016/110169 2016-12-15
CN2016110174 2016-12-15
CNPCT/CN2016/110174 2016-12-15
PCT/CN2017/089059 WO2018107699A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法

Publications (1)

Publication Number Publication Date
CN110167582A true CN110167582A (zh) 2019-08-23

Family

ID=62557856

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780078117.3A Pending CN110167582A (zh) 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法
CN201780078167.1A Pending CN110366427A (zh) 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780078167.1A Pending CN110366427A (zh) 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法

Country Status (7)

Country Link
US (2) US20190343930A1 (https=)
EP (2) EP3556386A4 (https=)
JP (2) JP7182793B2 (https=)
CN (2) CN110167582A (https=)
CA (2) CA3047171A1 (https=)
TW (4) TW202123962A (https=)
WO (3) WO2018107699A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113456579B (zh) * 2021-07-12 2023-04-25 南开大学 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN101573134A (zh) * 2006-08-28 2009-11-04 欧姆尼治疗有限公司 抗感染候选药物
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CN87104683A (zh) * 1986-05-15 1988-12-21 埃默里大学 改善血纤维蛋白溶解作用的组合物
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003210137A1 (en) * 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
EP1509236A4 (en) * 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
BR0316583A (pt) * 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
JP2008510814A (ja) * 2004-08-23 2008-04-10 ワイス Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
ES2516717T3 (es) * 2009-05-26 2014-10-31 Universidad De Salamanca Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
JP6085568B2 (ja) * 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
TN2016000048A1 (en) * 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
CA2939897A1 (en) * 2014-02-21 2015-08-27 Astellas Pharma Inc. New anti-human pai-1 antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN101573134A (zh) * 2006-08-28 2009-11-04 欧姆尼治疗有限公司 抗感染候选药物
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. RICHARD KITCHING 等: "Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis", 《J. EXP. MED.》 *
ELIZABETH J FISHER等: "Displacement of Tissue Bound Plasminogen by Glucose: A Possible Mechanism in the Pathogenesis of Diabetic Nephropathy", 《ELIZABETH J FISHER》 *

Also Published As

Publication number Publication date
TWI661838B (zh) 2019-06-11
WO2018107695A1 (zh) 2018-06-21
JP7242057B2 (ja) 2023-03-20
CN110366427A (zh) 2019-10-22
JP2020502135A (ja) 2020-01-23
TW201822793A (zh) 2018-07-01
EP3556388A1 (en) 2019-10-23
WO2018107700A1 (zh) 2018-06-21
JP2020502134A (ja) 2020-01-23
TW201822794A (zh) 2018-07-01
JP7182793B2 (ja) 2022-12-05
CA3047170A1 (en) 2018-06-21
CA3047171A1 (en) 2018-06-21
EP3556386A4 (en) 2020-07-08
US20190328848A1 (en) 2019-10-31
EP3556386A1 (en) 2019-10-23
TWI642441B (zh) 2018-12-01
WO2018107699A1 (zh) 2018-06-21
TW201822797A (zh) 2018-07-01
TW202123962A (zh) 2021-07-01
EP3556388A4 (en) 2020-07-08
US20190343930A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
Luo et al. The role of autophagy in steroid necrosis of the femoral head: a comprehensive research review
Liu et al. Treatment of non-traumatic avascular necrosis of the femoral head
RU2707254C1 (ru) Водный фармацевтический препарат и способ лечения хронической язвы
Itani et al. Prospective study of single-stage repair of contaminated hernias using a biologic porcine tissue matrix: the RICH Study
CN110167582A (zh) 一种预防和治疗药物性肾损伤的方法
Aggarwal et al. Cardiovascular safety of potential drugs for the treatment of coronavirus disease 2019
US20100278916A1 (en) Topical application and formulation of erythropoietin for skin wound healing
TW201603818A (zh) 組成物及方法
JP7109092B2 (ja) リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤
EP3154551B1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN110139668A (zh) 一种预防和治疗肝纤维化的方法
Bohn et al. Leg ulcer treatment outcomes with new ovine collagen extracellular matrix dressing: a retrospective case series
CN102961339A (zh) 一种含布洛芬微丸的缓释制剂的制备方法
JP5342695B2 (ja) ヒドロキシクロロキンを含有する痔核治療のための局所投与用注射剤組成物
US20160136324A1 (en) Biological film-forming agent for facilitation of wound healing and coating and protection of biological organs
RS64668B1 (sr) Montelukast za lečenje erozivnog osteoartritisa šake
Sanz-Reig et al. Single intravenous tranexamic acid dose to reduce blood loss in primary total knee replacement
E Elkhouly et al. Complications Associated Wound Healing In Diabetic Patients: Does Nanotechnology Have Any Superior Therapeutic Advantages?
Wu et al. A case of an acute kidney injury secondary to an implanted aminoglycoside
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
JP2018534306A5 (https=)
CN109966291A (zh) 化合物sb216763在制备预防和/或治疗脑血管疾病的药物中的应用及其药物组合物
CN112656938B (zh) 人参皂苷Re与溶菌酶在制备治疗或预防腹主动脉瘤药物中的应用
Fonteque et al. Exugunlation followed by fracture and avulsion of the distal phalanx in mare
Mader et al. Busulfan

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination